Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecologic tumor markers.

G J Olt1, A Berchuck, R C Bast

  • 1Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710.

Seminars in Surgical Oncology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic gene expression signature for high-grade serous ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Gynecologic oncology·2020
Same author

LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS: IGCS-0014 06. Ovarian Cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2015
Same author

Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).

Journal of internal medicine·2012
Same author

Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers.

Methods in molecular medicine·2011
Same author

Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

British journal of cancer·2009
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

Monoclonal antibody technology enhances tumor marker assays in gynecologic oncology, improving detection for ovarian cancer. Future research aims to develop novel markers for early screening and complement existing ones like CA 125.

Area of Science:

  • Gynecologic Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Monoclonal antibody technology has revolutionized tumor marker assays.
  • Availability of pure monoclonal antibodies enables highly sensitive serum marker assays.
  • Traditional assays for hCG, NB/70K, and TA-4 have been improved.

Purpose of the Study:

  • To highlight the utility of monoclonal antibody-based assays in gynecologic oncology.
  • To discuss the role of CA 125 in ovarian cancer monitoring and pelvic mass triage.
  • To identify future challenges and strategies for novel biomarker discovery in ovarian cancer.

Main Methods:

  • Development of highly sensitive assays using monoclonal antibodies against tumor-associated antigens.
  • Improvement of traditional tumor marker assays.

Related Experiment Videos

  • Exploration of strategies involving multiple markers and modalities for ovarian cancer screening.

    • Main Results:

    • CA 125 serves as a valuable first-generation marker for ovarian cancer monitoring, despite limitations.
    • Monoclonal antibody technology has improved existing tumor marker assays.
    • New diagnostic applications are emerging through immunohistochemistry and radionuclide imaging.

    Conclusions:

    • Monoclonal antibodies significantly enhance diagnostic capabilities in gynecologic oncology.
    • Further research is needed to identify novel biomarkers for early ovarian cancer detection and improved monitoring.
    • Integrating multiple markers and understanding tumor biology are key for future advancements.